132 related articles for article (PubMed ID: 23961597)
1. Canagliflozin: a new drug for type 2.
Goldman-Levine J
Diabetes Self Manag; 2013; 30(4):30, 32. PubMed ID: 23961597
[No Abstract] [Full Text] [Related]
2. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
3. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
4. Treating type 2 diabetes with canagliflozin.
Van Gilder D; Jungemann S
S D Med; 2013 Jul; 66(7):280-1. PubMed ID: 23957114
[No Abstract] [Full Text] [Related]
5. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
6. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
[TBL] [Abstract][Full Text] [Related]
7. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.
Neal B; Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Stein P; Desai M; Shaw W; Jiang J; Vercruysse F; Meininger G; Matthews D
Am Heart J; 2013 Aug; 166(2):217-223.e11. PubMed ID: 23895803
[TBL] [Abstract][Full Text] [Related]
8. Canagliflozin approved for type 2 diabetes.
Traynor K
Am J Health Syst Pharm; 2013 May; 70(10):834. PubMed ID: 23640337
[No Abstract] [Full Text] [Related]
9. [Canagliflozin. For treating diabetes].
Sabourin G
Perspect Infirm; 2013; 10(3):59. PubMed ID: 23705284
[No Abstract] [Full Text] [Related]
10. A novel approach.
Gebel E
Diabetes Forecast; 2013 Jun; 66(6):32-4. PubMed ID: 23802291
[No Abstract] [Full Text] [Related]
11. Canaglifozin (Invokana) for type 2 diabetes.
Med Lett Drugs Ther; 2013 May; 55(1416):37-9. PubMed ID: 23669782
[No Abstract] [Full Text] [Related]
12. A safety evaluation of canagliflozin : a first-in-class treatment for type 2 diabetes.
Boyle LD; Wilding JP
Expert Opin Drug Saf; 2014 Nov; 13(11):1535-44. PubMed ID: 25340618
[TBL] [Abstract][Full Text] [Related]
13. US approves "new class" of diabetes drug, under review in Canada.
Lange-Chenier H
CMAJ; 2013 Jul; 185(10):E470. PubMed ID: 23734031
[No Abstract] [Full Text] [Related]
14. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.
Washburn WN
J Med Chem; 2009 Apr; 52(7):1785-94. PubMed ID: 19243175
[No Abstract] [Full Text] [Related]
15. Canagliflozin: Improving diabetes by making urine sweet.
Vouyiouklis M
Cleve Clin J Med; 2013 Nov; 80(11):683-7. PubMed ID: 24186885
[TBL] [Abstract][Full Text] [Related]
16. Sodium glucose co-transporter 2 (SGLT2) inhibition with canagliflozin in type 2 diabetes mellitus.
Said S; Hernandez GT
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):203-6. PubMed ID: 24025022
[TBL] [Abstract][Full Text] [Related]
17. [Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Matthaei S
Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S59-64. PubMed ID: 24481634
[No Abstract] [Full Text] [Related]
18. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
20. [Introduction].
García SD
Med Clin (Barc); 2013 Sep; 141 Suppl 2():1-2. PubMed ID: 24444516
[No Abstract] [Full Text] [Related]
[Next] [New Search]
